Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis

Cited by (407)

Items 401–407 of 407

1. Kétamine : traitement d’action rapide de la crise suicidaire
   Hugo Bottemanne, Romain Colle · 2025 · Elsevier eBooks
2. Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project
   Michele De Prisco, Vincenzo Oliva, Alessandro Miola, Michele Fornaro, Elena Dragioti, Giovanni Croatto, Andre F Carvalho, Michael Berk, Katerina Nikolitch, Gayatri Saraf et al. · 2026 · BMJ
3. List of essential medicines for French psychiatry
   Hervé Javelot, Amélie Rousseau-Voisin, Mathilde Le Maoût, Guillaume Sujol, Stéphane Honoré, Davy Beauger, David Gourion, Antoine Yrondi · 2026 · L Encéphale
4. Feeling safe: an empirical-ethical analysis of vulnerability in (es)ketamine treatment
   Adrian Kind, Josephine Görke, Hannah Smirr, Christina Ni, Karen Yan, Dimitris Repantis · 2026 · BMC Medical Ethics
5. Ketamine’s mechanisms of action in major depressive disorder and treatment-resistant depression: Is brain topological change a candidate convergent systems-level pathway?
   Gia Han Le, Sabrina Wong, Simryn Selby, Roger S. McIntyre · 2026 · Asian Journal of Psychiatry
6. Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study
   G. S. Alves, Humberto M. M. Dos Santos, S. D. Damasceno, Laura M. Maciel, Otavio André Farias Sousa da Silva, Ciro Sousa de Moura Fé, Jilmario G. Santana, M. B. L. de Freitas, A. Carvalho, D. Monteiro · 2026 · Frontiers in Psychiatry
7. Suicidality during intranasal (es)ketamine treatment: A retrospective cohort study
   Yamina Ehrt‐Schäfer, Georgios Schoretsanitis, Erich Seifritz, Sebastian Olbrich, Stefano Ferrea · 2026 · Journal of Affective Disorders